Hikma Pharma

Hikma is a leading generic pharmaceutical company with a significant presence in the Middle East and North Africa (”MENA”) region, the United States and Europe. Currently, the group sells 369 pharmaceutical products in 767 dosage strengths and forms in 49 countries. 40 of our products are sold under promotion and distribution agreements with, or licenses from, 16 originator pharmaceutical companies and three generic pharmaceutical companies.

Its listing on the London Stock Exchange in November 2005 marked the beginning of an exciting new phase in the Company’s development. The financial flexibility that Hikma gained through the listing leaves it in a good position to grow, both organically and through acquisitions.

The group's strategy for growth is to build a strong and diverse product portfolio; to expand its geographic reach; to develop and leverage global research and development capabilities and API sourcing strengths; and to continue to maintain the very high standards of manufacturing capabilities.

The german company Ribosepharm, founded in 1983, was a mid-sized pharmaceutical company who boast 20 years of commitment to oncology with its products in cancer therapy. In January 2007 it became a member of the Hikma Group via acquisition.

Type:	NORMAL
Address:	Lochhamer Schlag 17, 82166 Gräfelfing
Website:	www.ribosepharm.de or www.hikma.com
Phone:	+49 (0)89 45 45 0-0